EP
The startup develops cell and gene therapy technologies that utilize biological vehicles for delivering therapeutic proteins directly into the central nervous system. This approach targets neurodevelopmental and neurological disorders, such as Rett syndrome, by enabling direct neuron protein replacement treatments for more effective disease management.
Updated 3 months ago
Funding
$810K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops cell and gene therapy technologies that utilize biological vehicles for delivering therapeutic proteins directly into the central nervous system. This approach targets neurodevelopmental and neurological disorders, such as Rett syndrome, by enabling direct neuron protein replacement treatments for more effective disease management.